UTAA06 (Peking Univ. Cancer Hospital and Inst.)

UTAA06 (Peking Univ. Cancer Hospital and Inst.): sourced facts only. name: "The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an "off-the-shelf" allogeneic B7-H3-targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3-positive solid tumors." [PMID:41779003]; target: "The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an "off-the-shelf" allogeneic B7-H3-targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3-positive solid tumors." [PMID:41779003]; developer: "Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Early Drug Development Center, Peking University Cancer Hospital and Institute, Beijing, China." [PMID:41779003]; modality: "UTAA06, an "off-the-shelf" allogeneic B7-H3-targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy" [PMID:41779003]